Suppr超能文献

升降薪胃汤通过改变肠道微生物群和肠道代谢稳态来改善抗生素相关性腹泻。

Shengjiang Xiexin Decoction ameliorates antibiotic-associated diarrhea by altering the gut microbiota and intestinal metabolic homeostasis.

机构信息

Department of Pharmacy, Beijing Friendsip Hospital, Capital Medical University, 100050, Beijing, China.

Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.

出版信息

Phytomedicine. 2023 May;113:154737. doi: 10.1016/j.phymed.2023.154737. Epub 2023 Mar 2.

Abstract

BACKGROUND

Antibiotic-associated diarrhea (AAD) has had a significant increase in the last years, with limited available effective therapies. Shengjiang Xiexin Decoction (SXD), a classic traditional Chinese medicine formula for treating diarrhea, is a promising alternative for reducing the incidence of AAD.

PURPOSE

This study aimed to explore the therapeutic effect of SXD on AAD and to investigate its potential therapeutic mechanism by integrated analysis of the gut microbiome and intestinal metabolic profile.

METHODS

16S rRNA sequencing analysis of the gut microbiota and untargeted-metabolomics analysis of feces were performed. The mechanism was further explored by fecal microbiota transplantation (FMT).

RESULTS

SXD could effectively ameliorate AAD symptoms and restore intestinal barrier function. In addition, SXD could significantly improve the diversity of the gut microbiota and accelerate the recovery of the gut microbiota. At the genus level, SXD significantly increased the relative abundance of Bacteroides spp (p < 0.01) and decreased the relative abundance of Escherichia_Shigela spp (p < 0.001). Untargeted metabolomics showed that SXD significantly improved gut microbiota and host metabolic function, particularly bile acid metabolism and amino acid metabolism.

CONCLUSION

This study demonstrated that SXD could extensively modulate the gut microbiota and intestinal metabolic homeostasis to treat AAD.

摘要

背景

近年来,抗生素相关性腹泻(AAD)的发病率显著增加,可用的有效治疗方法有限。 升麻泻心汤(SXD)是一种经典的治疗腹泻的中药方剂,可能是降低 AAD 发病率的一种有前途的替代方法。

目的

本研究旨在探讨 SXD 治疗 AAD 的疗效,并通过肠道微生物组和肠道代谢谱的综合分析探讨其潜在的治疗机制。

方法

对肠道微生物群进行 16S rRNA 测序分析,对粪便进行非靶向代谢组学分析。通过粪便微生物群移植(FMT)进一步探索机制。

结果

SXD 能有效改善 AAD 症状,恢复肠道屏障功能。此外,SXD 能显著改善肠道微生物群的多样性,并加速肠道微生物群的恢复。在属水平上,SXD 显著增加了拟杆菌属的相对丰度(p<0.01),降低了大肠埃希氏菌-志贺氏菌属的相对丰度(p<0.001)。非靶向代谢组学表明,SXD 能显著改善肠道微生物群和宿主代谢功能,特别是胆汁酸代谢和氨基酸代谢。

结论

本研究表明,SXD 能广泛调节肠道微生物群和肠道代谢稳态,从而治疗 AAD。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验